Literature DB >> 7052040

Advanced ovarian cancer: a prospective randomised trial of chlorambucil versus combined cyclophosphamide and cis-diamminedichloroplatinum.

D R Bell, R L Woods, J A Levi, R M Fox, M H Tattersall.   

Abstract

Thirty-seven patients with advanced ovarian cancer were treated in a prospective, randomised trial comparing chlorambucil with a combination of cyclophosphamide and cis-diamminedichloroplatinum (cis DDP). Treatment with the combination was associated with an increased overall response rate (69% versus 23%) (p = 0.04). A response was associated with a longer median survival but no survival advantage was demonstrated for patients who received cyclophosphamide/cis DDP. A larger study is needed to evaluate fully the potential of regimens containing cis DDP in the management of advanced ovarian cancer.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 7052040     DOI： 10.1111/j.1445-5994.1982.tb02469.x

Source DB:  PubMed          Journal:  Aust N Z J Med        ISSN： 0004-8291


  7 in total

1.  Treating ovarian cancer.

Authors:  R W Burslem; P M Wilkinson
Journal:  Br Med J (Clin Res Ed)       Date:  1986-10-18

Review 2.  Developing new drugs for ovarian cancer: a challenging task in a changing reality.

Authors:  R M Canetta; S K Carter
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

3.  In vitro evaluation of cisplatin interaction with doxorubicin or 4-hydroperoxycyclophosphamide against human gynecologic cancer cell lines.

Authors:  M J Xu; D S Alberts; R Liu; A Leibovitz; Y Liu
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

4.  Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group.

Authors: 
Journal:  BMJ       Date:  1991-10-12

5.  Prognostic factors in advanced epithelial ovarian cancer. (Gruppo Interregionale Cooperativo di Oncologia Ginecologica (GICOG)).

Authors:  S Marsoni; V Torri; M G Valsecchi; C Belloni; U Bianchi; G Bolis; C Bonazzi; N Colombo; A Epis; G Favalli
Journal:  Br J Cancer       Date:  1990-09       Impact factor: 7.640

6.  Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group.

Authors:  K Aabo; M Adams; P Adnitt; D S Alberts; A Athanazziou; V Barley; D R Bell; U Bianchi; G Bolis; M F Brady; H S Brodovsky; H Bruckner; M Buyse; R Canetta; V Chylak; C J Cohen; N Colombo; P F Conte; D Crowther; J H Edmonson; C Gennatas; E Gilbey; M Gore; D Guthrie; B Y Yeap
Journal:  Br J Cancer       Date:  1998-12       Impact factor: 7.640

7.  Dose intensity analysis in advanced ovarian cancer patients.

Authors:  V Torri; E L Korn; R Simon
Journal:  Br J Cancer       Date:  1993-01       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.